This report outlines a case series evaluating ruxolitinib as alternative graft-versus-host disease prophylaxis following mandatory tacrolimus withdrawal. The authors aimed to examine immunosuppressive transition strategies, dose ranges, patient safety parameters, and monitoring protocols in allogeneic stem cell transplantation.
Read more at Journal of Oncology Pharmacy Practice.
